JNJ-70218902
JNJ-70218902 is a bispecific antibody that binds to human TMEFF2 on cancer cells and to human CD3 on T cells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes T cell-mediated tumor cell killing (EC50: 1.4 nM) . JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003) [1].
Product Specifications
UNSPSC
12352203
Target
CD3; Transmembrane Glycoprotein
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[JNJ-70218902]
References & Citations
[1]Basu S et al. Abstract LB087: Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models Cancer Research 82.12_Supplement (2022) : LB087-LB087. |[2]Lowenstein C, et al. 1360 Pharmacodynamics of JNJ-70218902, a TMEFF2x CD3 bispecific antibody, in cynomolgus monkey. (2022) .
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6131187-01 0.1 mL
EVI2B (Protein EVI2B, Ecotropic Viral Integration Site 2B Protein Homolog, EVI-2B, CD361, EVDB) (AP)
Ask
View Details 
MBS6131187-02 5x 0.1 mL
EVI2B (Protein EVI2B, Ecotropic Viral Integration Site 2B Protein Homolog, EVI-2B, CD361, EVDB) (AP)
Ask
View Details 